234 related articles for article (PubMed ID: 26180925)
1. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
[TBL] [Abstract][Full Text] [Related]
2. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
[TBL] [Abstract][Full Text] [Related]
3. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
[TBL] [Abstract][Full Text] [Related]
4. KIR2DL4 promotes the proliferation of RCC cell associated with PI3K/Akt signaling activation.
Ding XF; Chen J; Ma HL; Liang Y; Wang YF; Zhang HT; Li X; Chen G
Life Sci; 2022 Mar; 293():120320. PubMed ID: 35063466
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib activates Axl signaling in renal cell cancer.
van der Mijn JC; Broxterman HJ; Knol JC; Piersma SR; De Haas RR; Dekker H; Pham TV; Van Beusechem VW; Halmos B; Mier JW; Jiménez CR; Verheul HM
Int J Cancer; 2016 Jun; 138(12):3002-10. PubMed ID: 26815723
[TBL] [Abstract][Full Text] [Related]
6. Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.
Zhu Q; Zhong AL; Hu H; Zhao JJ; Weng DS; Tang Y; Pan QZ; Zhou ZQ; Song MJ; Yang JY; He JY; Liu Y; Li M; Hu WM; Yang CP; Xiang T; Chen MY; Ma G; Guo L; Xia JC
J Hematol Oncol; 2020 Jan; 13(1):2. PubMed ID: 31900208
[TBL] [Abstract][Full Text] [Related]
7. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
8. Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.
Gustafsson A; Boström AK; Ljungberg B; Axelson H; Dahlbäck B
PLoS One; 2009 Oct; 4(10):e7575. PubMed ID: 19888345
[TBL] [Abstract][Full Text] [Related]
9. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
Xiao Y; Zhao H; Tian L; Nolley R; Diep AN; Ernst A; Fuh KC; Miao YR; von Eyben R; Leppert JT; Brooks JD; Peehl DM; Giaccia AJ; Rankin EB
Cancer Res; 2019 Nov; 79(22):5758-5768. PubMed ID: 31585940
[TBL] [Abstract][Full Text] [Related]
10. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
Hao P; Kang B; Li Y; Hao W; Ma F
Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic Expression of AXL Is Associated With High Risk of Postoperative Relapse of Conventional Renal Cell Carcinoma.
Peterfi L; Bjercke T; Yusenko MV; Kovacs G; Banyai D
Anticancer Res; 2020 Jun; 40(6):3485-3489. PubMed ID: 32487648
[TBL] [Abstract][Full Text] [Related]
12. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
13. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
[TBL] [Abstract][Full Text] [Related]
14. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
Huang J; Wang X; Wen G; Ren Y
Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
[TBL] [Abstract][Full Text] [Related]
16. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
17. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
[TBL] [Abstract][Full Text] [Related]
18. Expression of the proto-oncogene Axl in renal cell carcinoma.
Chung BI; Malkowicz SB; Nguyen TB; Libertino JA; McGarvey TW
DNA Cell Biol; 2003 Aug; 22(8):533-40. PubMed ID: 14565870
[TBL] [Abstract][Full Text] [Related]
19. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages.
Gustafsson A; Fritz HKM; Dahlbäck B
Exp Cell Res; 2017 Jun; 355(1):47-56. PubMed ID: 28327411
[TBL] [Abstract][Full Text] [Related]
20. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]